Literature DB >> 27033928

Proteomic and ultrastructural analysis of the effect of a new nitazoxanide-N-methyl-1H-benzimidazole hybrid against Giardia intestinalis.

Félix Matadamas-Martínez1, Rafael Castillo2, Alicia Hernández-Campos2, Carlos Méndez-Cuesta2, Wanderley de Souza3, Ana Paula Gadelha3, Benjamín Nogueda-Torres4, José Manuel Hernández5, Lilián Yépez-Mulia6.   

Abstract

In an effort to develop alternative drugs for the treatment of giardiasis our research group has synthesized and evaluated a novel nitazoxanide and N-methyl-1H-benzimidazole hybrid molecule, named CMC-20. It showed an IC50 of 0.010 μM on Giardia intestinalis, lower than the IC50 values of 0.015, 0.037 and 1.224 μM for nitazoxanide, albendazole and metronidazole, respectively. In addition, we report studies carried out on its mechanism of action and effect at the ultrastructural level on G. intestinalis. The proteomic analysis of trophozoites treated with CMC-20 revealed significant changes in the expression level of proteins of the cytoskeleton, alpha and beta tubulin, alpha-1, beta giardin and axoneme-associated protein, among other molecules. Ultrastructural studies demonstrated that CMC-20 induces morphological changes on the parasite that loses its characteristic pear shape. Uncommon large bulbous structure at the flagella end, and parasites showing flange membrane bending and a concave depression in the ventral region, resembling an encystation process, were also observed. In addition, some apoptotic and autophagic-like features, such as membrane blebbing, intense vacuolation, chromatin condensation and multilamellar bodies were detected. Phosphatidylserine externalization was determined as an apoptotic marker by flow cytometry and immunofluorescence microscopy; however, a typical ladder-like DNA fragmentation profile was not detected. Although it was found that CMC-20 triggers the encystation process, damage to the cyst wall indicates loss of viability.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Apoptosis-like; G. intestinalis; Hybrid compound

Mesh:

Substances:

Year:  2016        PMID: 27033928     DOI: 10.1016/j.rvsc.2016.02.006

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  4 in total

Review 1.  An Overview of Mucosa-Associated Protozoa: Challenges in Chemotherapy and Future Perspectives.

Authors:  Helena Lucia Carneiro Santos; Karina M Rebello
Journal:  Front Cell Infect Microbiol       Date:  2022-04-25       Impact factor: 6.073

2.  Species-Specific Inactivation of Triosephosphate Isomerase from Trypanosoma brucei: Kinetic and Molecular Dynamics Studies.

Authors:  Alejandra Vázquez-Raygoza; Lucia Cano-González; Israel Velázquez-Martínez; Pedro Josué Trejo-Soto; Rafael Castillo; Alicia Hernández-Campos; Francisco Hernández-Luis; Jesús Oria-Hernández; Adriana Castillo-Villanueva; Claudia Avitia-Domínguez; Erick Sierra-Campos; Mónica Valdez-Solana; Alfredo Téllez-Valencia
Journal:  Molecules       Date:  2017-11-24       Impact factor: 4.411

3.  On the molecular and cellular effects of omeprazole to further support its effectiveness as an antigiardial drug.

Authors:  Gabriel López-Velázquez; Cynthia Fernández-Lainez; José Ignacio de la Mora-de la Mora; Daniela Caudillo de la Portilla; Rafael Reynoso-Robles; Angélica González-Maciel; Cecilia Ridaura; Itzhel García-Torres; Pedro Gutiérrez-Castrellón; Alfonso Olivos-García; Luis Antonio Flores-López; Sergio Enríquez-Flores
Journal:  Sci Rep       Date:  2019-06-20       Impact factor: 4.379

4.  Characterisation of the in vitro activity of a Nitazoxanide-N-methyl-1H-benzimidazole hybrid molecule against albendazole and nitazoxanide susceptible and resistant strains of Giardia intestinalis and its in vivo giardicidal activity.

Authors:  Félix Matadamas-Martínez; Benjamín Nogueda-Torres; Rafael Castillo; Alicia Hernández-Campos; María de la Luz Barrera-Valdes; Gloria León-Ávila; José Manuel Hernández; Lilián Yépez-Mulia
Journal:  Mem Inst Oswaldo Cruz       Date:  2020-02-07       Impact factor: 2.743

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.